论文部分内容阅读
目的:探讨联合应用胸腺肽和抗结核药对复治涂阳肺结核进行治疗的临床效果。方法:随机选取2010年4月-2015年9月在我院接受治疗的78例复治涂阳肺结核患者平分2组,对照组给予常规化疗,观察组给予胸腺肽+抗结核药治疗,对比分析2组临床治疗效果。结果:观察组的治疗总有效率、痰菌阴转率、空洞闭合率分别为94.87%、94.87%、79.49%,均明显高于对照组,组间差异比较存在显著性(P<0.05);观察组不良反应发生率为7.69%,与对照组比较无显著性差异(P>0.05)。结论:联合应用抗结核药和胸腺肽对复治涂阳肺结核患者进行治疗可取得更为理想的临床疗效。
Objective: To investigate the clinical effect of combined application of thymosin and antituberculosis drugs in the treatment of retreatment smear positive pulmonary tuberculosis. Methods: 78 cases of retreated smear-positive pulmonary tuberculosis treated in our hospital from April 2010 to September 2015 were randomly divided into two groups. The control group was given conventional chemotherapy, and the observation group was given thymosin + antituberculotic treatment. The comparative analysis of 2 Group clinical treatment effect. Results: The total effective rate, sputum negative conversion rate and void closure rate in the observation group were 94.87%, 94.87% and 79.49%, respectively, which were significantly higher than those in the control group (P <0.05). The incidence of adverse reactions in the observation group was 7.69%, no significant difference compared with the control group (P> 0.05). Conclusion: The combination of anti-tuberculosis drugs and thymosin in the treatment of retreatment smear-positive pulmonary tuberculosis patients can achieve a more satisfactory clinical effect.